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Nipple aspirate cytology and pathologic parameters
predict residual cancer and nodal involvement after
excisional breast biopsy
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Summary We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour
size after excisional biopsy (EB), although normal NAF cytology did not exclude RC. Tumour size correlates with the risk of lymph node (LN)
metastases. LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant
therapy. We hypothesized that pathologic factors known after EB, combined with NAF cytology, would predict with a high degree of accuracy
the presence of RC and LN spread. NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and
multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size,
tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated
bivariately and then by logistic regression (LR) for their association with RC and involved LN (≥ 1 (+) LN, useful to determine chemotherapy
need, and ≥ 4 (+) LN, useful to determine radiation need to the chest and axilla). Data were analysed using NAF cytology alone, pathologic
parameters alone, and NAF cytology and pathologic parameters combined. The combined LR model was superior in predicting residual
cancer (94%) to LR models using NAF cytology (36%) or pathologic parameters (75%) alone. When only subjects with normal NAF cytology
were evaluated by LR, the model was 92% sensitive in predicting RC. Tumour size and NAF cytology predicted which patients had ≥ 1 (+) LN,
whereas tumour and specimen size predicted which patients had ≥ 4 (+) LN. We propose an alogorithm which, if confirmed in a larger study,
may allow clinicians to be more selective in their recommendations of re-excision breast biopsy or mastectomy. © 2001 Cancer Research
Campaign http://www.bjcancer.com
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Thousands of women undergo re-excision breast biopsy or
mastectomy each year to obtain optimal control of their disease,
but only approximately half will be found to have residual cancer.
We were encouraged by our prior findings which demonstrated
that abnormal (atypical or malignant) nipple aspirate fluid (NAF)
cytology was 97% accurate in predicting the presence of residual
cancer in the breast. All cases with malignant NAF cytology had
residual cancer. Nonetheless, most subjects (57/72, 79%) had
normal cytology (not atypical or malignant). The presence of
normal NAF cytology did not exclude residual cancer, suggesting
that NAF cytology was not sufficiently sensitive to be used alone
as a predictor of residual cancer in the breast. Prior studies have
demonstrated that clinical parameters such as tumour size (Tafra
et al, 1993), tumour at the biopsy margin(s), gross multicentricity
and extensive DCIS (Harris et al, 1993; Jordan et al, 1998; Lagios,
1992) are predictive of residual breast cancer, although no one
marker is sufficiently sensitive nor specific to be used in clinical
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practice. Tumour size, as well as grade, are correlated with the
presence of lymph node metastases (Bland and Copeland, 1998). It
was our hypothesis that by combining NAF cytology with pathologic parameters we would increase our ability to predict which
women had residual breast cancer and lymph node metastases. If
our hypothesis proved correct, it might be possible to be more
selective in our determination of who should have additional
surgery, as well as adjuvant chemohormonal and radiation therapy.
This study would also allow us to determine which of the markers
are most predictive of residual breast cancer and nodal spread.
We chose to include those women who had undergone excisional
breast biopsy that we evaluated in our last report, so that the best
comparison could be made regarding the importance of pathologic
parameters over and above NAF cytology. We selected parameters
which could be obtained prior to re-excision or mastectomy, so that
they would be most applicable to the clinical situation.
Present efforts to evaluate the breast directly either through
evaluation of tissue or individual cells have been hindered because
the analysis of these specimens generally required an invasive
procedure. The adult non-pregnant, non-lactating breast secretes
fluid into the breast ductal system. This fluid can be obtained
through aspiration of the nipple with a modified breast pump.
Nipple aspiration has the attractiveness of quickly, painlessly, and
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non-invasively obtaining breast epithelial cells, the cells at risk for
transformation to breast cancer. We are now able to obtain cellular
NAF samples (≥ 10 breast epithelial cells on a slide) in the
majority of subjects (Sauter et al, 1997). Those samples which
contain few or no breast epithelial cells are also informative, for
we have also shown that NAF cytology of low cellularity is associated (p = 0.001) with a low breast cancer risk (Sauter et al,
1997).
The pathologic parameters chosen for analysis are of proven or
suspected importance in predicting whether a woman has residual
breast cancer. We previously demonstrated that abnormal NAF
cytology is associated with residual breast cancer and tumour size
(Sauter et al, 1999). The goal of this study is to determine if NAF
cytology combined with pathologic parameters will increase our
ability to predict the presence of residual breast cancer and lymph
node metastases after excisional biopsy. If we can predict which
subjects have residual cancer and/or lymph node metastases, this
should prove useful to guide therapy regarding further surgery,
chemohormonal and/or radiation therapy.
MATERIALS AND METHODS
Subjects
Seventy-two specimens from 70 subjects aged 30–79 (median 52)
years were collected for the study between January 1995 and July
1997 after approval of the Institutional Review Board. Each breast
had undergone excisional biopsy demonstrating ductal carcinoma
in situ (DCIS) or invasive cancer. A mastectomy was performed
a median of 22 (range 2–84) days after excisional biopsy, with
the exception of three subjects who received neoadjuvant
chemotherapy prior to mastectomy. The subject was determined to
have residual cancer if either invasive carcinoma (IC) or DCIS
was present in the breast, or no residual cancer if neither IC or
DCIS was present. (The latter category included subjects whose
specimens contained lobular carcinoma in situ (LCIS), atypical
hyperplasia (AH), hyperplasia without atypia, or normal breast
tissue.)
Excisional biopsy margins were involved in 52/72 (72%), close
in 18/72 (25%), or unknown in 2/72 (3%). Pathology records were
also reviewed for tumour multifocality (independent tumours in
the same breast quadrant) or multicentricity (independent breast
tumours in more than one quadrant), type of ductal carcinoma in
situ (DCIS) and/or invasive cancer, grade of in situ and/or invasive
cancer, tumour and specimen size (we used biopsy cavity size as a
surrogate for specimen size, since information on specimen size
was not available for all subjects), tumour and biopsy cavity quadrant, the presence or absence of extensive DCIS, distance of the
biopsy scar from the nipple, and ER/PR status. The variables
included in the final logistic model were based on sample size and
predictive strength of the model.

If keratin plugs rather than NAF were obtained after suction was
completed, the plugs were removed with an alcohol swab and
suctioning repeated. On some occasions, this procedure was
repeated two or three times to remove the plugs before fluid was
obtained. In order to obtain additional fluid, the nipple was gently
compressed. One or two additional droplets of fluid often
appeared.
Cytology
A. Specimen preparation
The NAF was collected in 50 µl capillary tubes and rinsed into a
container with 1 ml of 3% polyethylene glycol in ethanol/
isopropanol. The specimen was then cytocentrifuged onto 10 glass
slides. Three of the slides were used for cytologic examination. If
the slides contained < 10 epithelial cells, two additional slides
were examined. The remaining slides (5 or 7) were stored for
biomarker studies. The slides selected for cytologic examination
were washed twice in 95% ethanol for 10 min each, rehydrated in
tap water and stained by the Papanicolaou method.
B. Specimen interpretation
The Papanicolaou-stained smears were examined by a cytopathologist (HE) experienced with breast cytology. The examiner was
not aware of the histopathologic findings of each specimen.
Moreover, since the NAF specimens analysed in this study were
mixed with specimens from subjects with an intact breast, the
examiner was not aware of which NAF specimens were from
mastectomies. Each specimen was designated as containing scant
epithelial cells (Class I), normal epithelial cells (Class IIA), hyperplasia without atypia (Class IIB), atypia (Class III), or malignant
cells (Class IV), using criteria previously described (Sauter et al,
1997). This is a modification of terminology used by King et al
(1983), and is to be differentiated from the Papanicolaou classification.
Histology
A. Specimen preparation
The breast specimen was fixed in 10% neutral buffered formalin
for 16–24 h and embedded in paraffin wax. Eighteen to 20 representative blocks were prepared, and one 4 µm slide per block was
cut and stained with haematoxylin and eosin (H&E).
B. Specimen interpretation
Histologic review of each H&E slide from the excisional biopsy
and mastectomy was performed. Margin status was assessed in the
excisional biopsies. A margin was defined as positive if tumour
was present at the margin, close if tumour was present ≤ 2 mm
from the margin, and negative if present > 2 mm from the margin.
Statistical analysis

Aspiration technique
Nipple fluid was aspirated by a trained physician or nurse clinician
using a modified breast pump (Sauter et al, 1996). The breast
nipple was cleansed with alcohol, the device was placed over the
nipple/areolar complex and the plunger of the aspiration device
was withdrawn to the 7 ml level and held for 15 s. Fluid in the
form of droplets was collected in capillary tubes. The quantity of
fluid varied from 1 µl to 200 µl.
© 2001 Cancer Research Campaign

Bivariate analyses were performed between biomarker characteristics and residual cancer in the breast, the presence of one or more
positive lymph nodes and the presence of four or more positive
lymph nodes (Table 1). To test for significance, the difference of
proportions t-test was employed for dichotomous independent
variables (Brown and Hollander, 1977; Jordan et al, 1998). For
independent variables with three or more ordered categories,
Somer’s D (asymmetric extension of gamma statistic) was applied,
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1954 ER Sauter et al

Table 1
status

Bivariate analysis of biomarker characteristics by residual disease in the breast1 and by lymph node

Residual breast cancer

Positive lymph nodes
1 or more

4 or more

Yes

No

Yes

No

Yes

No

Cytology (n = 72)
Normal
Atypical or malignant

25***
14

32
1

19*
11

38
4

7
3

50
12

Tumour characteristics (n = 71)
Multifocal disease
Multicentric disease
Neither

15
5
19

9
1
22

8
2
19

16
4
22

2
0
7

22
6
34

Specimen size in cm (n = 72)
<1
1–1.9
2–2.9
3–3.9
4–4.9
≥5

12
11
3
9
2
2

4
8
7
10
1
3

9
6
3
7
1
4

7
13
7
12
2
1

1
2
2
2
1
2

15
17
8
16
2
4

Biopsy margins (n = 67)
Negative/close
Positive

7**
29

16
15

7
19

16
25

2
6

21
38

Primary tumour size in cm (n = 71)
in situ
<2
2–4.9
≥5
invades other tissues

7*
11
12
6
3

8
16
6
2
0

1***
6
13
6
3

14
21
5
2
0

0*
3
3
3
0

15
24
15
5
3

Tumor grade (n = 65)
1
2
3

3
15
18

5
12
12

1**
9
18

7
18
12

0#
3
6

8
24
24

Scar distance from the nipple in cm (n = 50)
<1
2
1–2.9
3
3–4.9
11
5+
11

0
5
10
8

1
3
5
8

1
5
16
11

0
0
3
3

2
8
18
16

Extensive DCIS (n = 64)
No
Yes

20
14

24
6

20
8

24
12

9
0

35
20

Estrogen receptor (n = 53)
Negative
Positive

5
24

8
16

7
19

6
21

3
6

10
34

Progesterone receptor (n = 52)
Negative
Positive

15
14

10
13

14
12

11
15

5
4

20
23

1
The bivariate relationships between surgery result (residual cancer present or absent) and cytology, biopsy
margins, nipple involvement, EIC, ER and PR were tested using the Difference of Proportions test (Brown
and Hollander, 1977; Jordan et al, 1998). The bivariate relationships between surgery result and specimen
size, primary tumour size, residual tumour size, tumour characteristics, tumour grade and scar distance from
the nipple were tested using the Somer’s D statistic for ordered categories (Everitt, 1977).
***P < 0.001, **P < 0.01, *P < 0.05, #P < 0.10

which is preferential to other non-parametric tests such as MannWhitney and Kruskall-Wallis in situations where there are a
limited number of ordered categories (Everitt, 1977).
Stepwise logistic regression models (Agresti, 1990) were fit to
the data to determine whether residual cancer in the breast was
associated with cytologic grouping and pathologic parameters for
which data were available the vast majority of subjects and on
bivariate analysis contributed to the model. The pathologic parameters included specimen margins, specimen size, presence of
multifocality and/or multicentricity, and tumour size. The same
pathologic parameters were used to determine the best model to
British Journal of Cancer (2001) 85(12), 1952–1957

predict the presence of lymph node status: either 0 vs 1 or more
positive lymph nodes, or 0–3 vs 4 or more positive lymph nodes.
Initially we evaluated all subjects, and then an important subgroup, those with normal cytology (no atypia or carcinoma).
RESULTS
We first determined the bivariate relationships between NAF
cytology and pathologic parameters with the presence of residual
breast cancer and lymph node involvement (Table 1). Abnormal
NAF cytology (P < 0.001), positive biopsy margins (P < 0.01) and
© 2001 Cancer Research Campaign
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large primary tumour size (P < 0.05) were associated with the
presence of residual breast cancer. Large primary tumour size
(P < 0.001), high tumour grade (P < 0.01) and abnormal NAF
cytology (P < 0.05) were associated with the presence of ≥ 1
positive lymph nodes, whereas only large primary tumour size
(P < 0.05) and tumour grade (P < 0.10) were associated with ≥ 4
positive lymph nodes.
Taking into consideration both sample size and bivariate relationships, cytology, tumour size, the presence of multifocality
and/or multicentricity, specimen size, and margin status were
considered in our final logistic regression model. Forward selection stepwise logistic regression was first implemented on the
entire data set. In a prior publication we demonstrated that subjects
with abnormal (atypical or malignant) NAF cytology after excisional biopsy were very likely to have residual breast cancer. Next,
we evaluated pathologic parameters which could help predict the
presence of residual breast cancer in subjects with normal NAF
cytology. In the latter group, NAF cytology was of no help in
predicting residual breast cancer. The four pathologic parameters:
presence of multifocality and/or multicentricity, tumour size, specimen size and margin status led to a model (Table 2) which was
highly sensitive (92%) and specific (80%) in predicting residual
breast cancer (R2 = 0.460).
Table 2

For our entire data set (Table 2), the partial effects of NAF
cytology (P < 0.001), margin status and presence of multifocality
and/or multicentricity (P < 0.01 for both), and specimen size (P <
0.05) were found to be significantly associated with the risk of
residual cancer. Tumour size was not significant in the regression
model mainly because of its shared correlation with margin status,
which is a better predictor of residual breast cancer. The resulting
four markers yielded a highly predictive model (R2 = 0.593) for
residual breast cancer. In this way, we increased the sensitivity of
non-invasive methods to predict residual breast cancer from 36%
using NAF cytology alone to 94% using all four markers. NAF
cytology proved to be an important addition to pathologic factors,
for when information for NAF cytology was not available, the
predictive value (R2 = 0.294 vs 0.593) and the sensitivity of the
model declined (75% vs 94%).
We used the same parameters in our models of all subjects, and
those with normal cytology, to predict which subjects had involved
lymph nodes (Table 3). When subjects with normal cytology were
evaluated, only tumour size was significantly predictive of the
presence of both one or more positive nodes (P < 0.001) as well as
four or more positive nodes (P < 0.05). For all subjects, tumour
size (P < 0.001) and cytology (P < 0.05) were significant in the
model (R2 = 0.475) to determine which subjects had one or more

Stepwise logistic regression results for all specimens in the model of residual breast cancer1

Dependent (independent)
Variables

Nagelkerke
R2

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Normal cytology
(margins**, mf/mc2, *, specimen size*
and tumour sizeNS)

0.474

22/24 (92)

24/30 (80)

22/28 (79)

24/26 (92)

All subjects
(cytology***, margins**, mf/mc**,
specimen size* and tumour sizeNS)

0.593

34/36 (94)

24/31 (77)

34/41 (83)

24/26 (92)

1

Complete data were available for 54 of 57 subjects with normal cytology and 67 of 72 total subjects. 2mf/mc: Presence of
either multifocal or multicentric disease. Two additional independent variables were examined in separate models but not
included because they decreased the sample to < 60 and had only minor impact. ***P < 0.001, **P < 0.01, *P < 0.05,
#
P < 0.10, NS not significant.

Table 3

Stepwise logistic regression results for number of lymph nodes involved with cancer1

Dependent (independent)
variables
Normal cytology
zero vs one or more
(tumour size***, mf/mc2, NS,
specimen sizeNS and biopsy marginsNS)
0–3 vs 4 or more
(tumour size*, specimen sizeNS, mf/mcNS
and biopsy marginsNS)
All subjects
zero vs one or more
(tumour size***, cytology*, specimen sizeNS,
mf/mcNS and biopsy marginsNS)
0–3 vs, 4 or more
(tumour size*, specimen size# and cytologyNS,
mf/mcNS and biopsy marginsNS)

Nagelkerke
R2

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

0.344

12/17 (71)

30/37 (81)

12/19 (63)

30/35 (86)

0.157

0/6 (0)

48/48 (100)

0/0 (–)

48/54 (89)

0.475

20/26 (77)

33/41 (81)

20/28 (71)

33/39 (85)

0.207

1/8 (13)

59/59 (100)

1/1 (100)

59/66 (89)

1

Complete data was available for 54 of 57 subjects with normal cytology. 2mf/mc: Presence of either multifocal or multicentric disease. Due to the
limited sample size, a moderate to strong predictive relationship is required for statistical significance. ***P < 0.001, **P < 0.01, *P < 0.05,
#
P < 0.10, NS not significant.
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Excisional breast biopsy (36/67 with RC)

re-excision or mastectomy

atypical or malignant cytology (12/13 with RC)

Normal cytology (24/54 with RC)

re-excision or mastectomy

multifocal/multicentric (mf/mc) tumour (14/24 with RC)

No mf/mc disease (10/30 with RC)

re-excision or mastectomy

positive biopsy margins (9/21 with RC)

Close biopsy margins (1/9 with RC)

re-excision or mastectomy

biopsy scar ≥4 cm from nipple (1/1 with RC)

Biopsy scar < 4 cm from niple (0/8 with RC)

consider no further surgery

Figure 1 Need for re-excision breast biopsy or mastectomy. Algorithm to determine which subjects have residual breast cancer (RC). This is based on a
limited sample set and must be confirmed before being used in clinical practice to determine the need for re-excision breast biopsy or mastectomy.

positive lymph nodes, while tumour size (P < 0.05) and specimen
size (P < 0.10) were significant in predicting which subjects had
four or more positive lymph nodes.
Our logistic regression model considers NAF cytology and pathologic parameters together in order to determine the presence of
residual breast cancer or lymph node spread. An alternative way to
look at the predictors is by developing a decision tree, or algorithm
(Figure 1). Using this strategy, the combination of normal cytology,
absence of multifocality or multicentricity, close biopsy margins and
biopsy scar < 4 cm from the nipple defined a population of women
who were all free of residual breast cancer. These eight women
comprise 26% (8/31) of the women in the model who did not have
residual disease. We attempted to develop an algorithm which
defined subjects in our data set who had negative lymph nodes, but
it was not sufficiently discriminative (data not shown).
DISCUSSION
When we initiated this study, we wished to identify markers in
NAF which were associated with residual cancer in the breast and
disease spread to lymph nodes. In our prior report, we evaluated
subjects diagnosed by either needle or excisional biopsy. However,
since 100% of the mastectomies performed after needle biopsy
alone had residual DCIS or invasive cancer, in this study we chose
to focus on subjects with presumed residual disease after excisional
biopsy, in which only 39/72 (54%) mastectomies performed
contained residual DCIS or invasive cancer.
After excisional biopsy, many women undergo mastectomy for
presumed residual cancer. Thousands of women who undergo
British Journal of Cancer (2001) 85(12), 1952–1957

mastectomy after excisional biopsy will not have in situ or invasive cancer found in the mastectomy specimen. The chance of
finding residual cancer is related to tumour margin status in the
diagnostic specimen. If the margin is close, the likelihood is
23–32%; if positive, 53–65%; and if unknown, approximately
45% (Frazier et al, 1989; Gwin et al, 1993). In our prior publication, we reported that NAF cytology (normal vs atypical or malignant) was 97% specific but only 36% sensitive in predicting the
presence of residual cancer, with the only false positive coming
from a specimen demonstrating atypia.
The breast ducts of adult non-pregnant women secrete small
amounts of fluid (Keynes, 1923). This fluid does not escape
because the nipple ducts are occluded by smooth muscle contraction, dried secretions, and keratinized epithelial plugs. Breast fluid
can be obtained by nipple aspiration in a significant proportion of
women without spontaneous nipple discharge with the use of a
modified breast pump (Petrakis et al, 1975). This fluid contains
several types of cells, including exfoliated breast epithelial cells
(King et al, 1975). Because breast cancer develops from ductal and
lobular epithelium, NAF is a potentially useful epidemiologic and
clinical research tool.
Wrensch et al (1992) evaluated NAF in a cohort of subjects with
normal breast cancer risk. In this population, they demonstrated
that subjects with NAF which contained normal cytology, hyperplasia without atypia, or atypical hyperplasia have a risk of breast
cancer similar to subjects who have a biopsy with a similar diagnosis. We found (Sauter et al, 1999) that malignant cells in NAF
after excisional biopsy were 100% and atypical cells 88% predictive of the presence of residual breast cancer.
© 2001 Cancer Research Campaign
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Since NAF cytology is only 36% sensitive in detecting residual
cancer, a finding of abnormal NAF cytology is highly suggestive
of the presence of residual cancer, but normal cytology does not
exclude the possibility that residual cancer exists. We therefore
evaluated pathologic markers known to be associated with breast
cancer, to determine if we could increase our ability to predict the
presence of residual disease.
NAF cytology, the presence of multifocality and/or multicentricity, specimen size, and biopsy margins were the characteristics
which helped to create the best model to predict the presence of
residual breast cancer. Using this combination of markers, we
were able to increase our sensitivity from 36% to 94%. NAF
cytology is an important predictor of residual cancer, for without it
the association drops from R2 = 0.59 to R2 = 0.29, and the sensitivity decreases from 94% to 75%. For subjects with normal
cytology, the model is 92% sensitive in predicting the presence of
residual breast cancer. This dramatic increase in sensitivity
resulted in a decrease in specificity of 15–20% compared to the
examination of NAF cytology alone.
We developed an algorithm (Figure 1) which correctly identified 26% of women who did not have residual breast cancer. These
findings are preliminary and certainly need to be reproduced in a
larger multi-institutional study. If confirmed, the algorithm may be
useful in helping clinicians to determine who should and should
not undergo re-excision breast biopsy or mastectomy.
We found that both NAF cytology and pathologic parameters
contributed to the model which best predicted the presence of
residual breast cancer and nodal spread, and that the combination
of parameters was both highly sensitive and specific in predicting
residual cancer and moderately sensitive but highly specific in
predicting nodal spread. These findings provide insight into breast
cancer tumour development and progression, and may prove
useful in guiding therapy.
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